Actively Recruiting
Evaluating NEU-411 Compared to Placebo in Adults With Early Parkinsons Disease Using Genetic Testing and an Open-Label Extension
Led by Neuron23 Inc. · Updated on 2026-10-30
150
Participants Needed
72
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and effectiveness of NEU-411 in people aged 40 to 80 years with early Parkinsons Disease PD who have a specific genetic profile that predicts increased activity in the LRRK2 pathway. This Phase 2 study uses a companion diagnostic genetic test to identify participants with LRRK2-driven PD. The trial aims to compare NEU-411, a brain-penetrant drug that inhibits LRRK2 activity, to a placebo. Participants will be randomly assigned to receive either NEU-411 30 mg once daily or a matching placebo for 52 weeks. After this double-blind treatment period, there will be a safety follow-up visit within two weeks. Those who qualify may continue into an open-label extension phase where they will receive NEU-411 for an additional 26 weeks. Throughout the study, participants will have their Parkinsons symptoms and safety monitored using digital biomarker scores and clinical rating scales. Researchers will assess changes from baseline in the Roche digital biomarker score and the Unified Parkinsons Disease Rating Scale over the 52-week treatment period. Safety will be tracked by recording adverse events through the end of the study. Total participation may last up to 78 weeks including the extension and follow-up.
CONDITIONS
Brief Title
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Research Team
F
Fatta B Nahab, MD, FAAN, FANA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here